We're Still Here: Indigenous Resilience and Healing from Intergenerational Trauma

Date and time: 26 Mar 2022 from 10:15 to 11:15

Location: Virtual  Floor Map
Presented by Dr. Nel Wieman: MSc, MD, FRCPC, Little Grand Rapids First Nation, Anishinaabe Nation, Deputy Chief Medical Officer, Office of the Chief Medical Officer (OCMO)

As psychiatrists encountering Indigenous (First Nations/Metis/Inuit) patients in the clinical setting, it is important to continually develop one's practice of cultural humility, through learning more about Canada's historical and contemporary treatment of Indigenous peoples and its impact on perpetuating intergenerational trauma as well as being open to considering two-eyed seeing approaches to treatment
and overall management, thereby increasing the cultural safety of mental health services and resulting in more optimal patient outcomes.

Learning Objectives:
Objective #1 To increase learnings related to the mental health status of Canada's of Indigenous peoples
Objective #2 To increase knowledge about intergenerational trauma, its causes and management
Objective #3 To increase familiarity with the concept of two-eyed seeing and its applicability to psychiatric treatment of Indigenous peoples

Literature References

Graham, S., Stelkia, K., Wieman, C., & Adams, E. (2021). Mental health interventions for First Nation, Inuit, and Métis peoples in Canada: A systematic review. The International Indigenous Policy Journal, 12(2).

Indigenous Health Primer (2019) Royal College of Physicians and Surgeons of Canada. indigenous-health-e

(MOC Program credits for this foundational reading document above: Two (2) credits per hour, Section 2 Self-learning: Planned learning: Personal Learning Project)

Martin, D. (2012). Two-eyed seeing: A framework for understanding Indigenous and non-Indigenous approaches to Indigenous health research. Canadian Journal of Nursing Research, 44(2): 20-42.


Disclosure of Conflict of Interest

  1. Do you have a relationship with a for-profit and/or a not-forprofit organization to disclose?


  1. All other investments or relationships that could be seen by a reasonable, well-informed participant as having the potential to influence the content of the educational activity


  1. Patents on a drug, product, or device


  1. Funded grants or clinical trials


  1. Membership on advisory boards or speakers' bureaus

See below

  1. Any direct financial payments including receipt of honoraria

I sit on the Board of Directors of Pacific Blue Cross and receive honoraria for preparation/reading of materials and attendance at quarterly board meetings and subcommittee meetings (Governance and Human Resources Subcommittees) totally approximately $10K/year.

  1. I acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.


  1. I intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e., "off-label" use of medication). Note: You must declare all off-label use to the audience during your presentation


  1. By clicking "I agree", you are acknowledging that the information provided is accurate and that you understand that this information will be publicly available.

I agree


Add to Calendar